// App-Quantinova.ai

154 : MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.

Researchers

Presenter

  • Martin Scurr

Principal Investigators

  • Tom Pembroke

  • Richard Adams

  • Daniel Blount

  • Alison Brewster

  • Sarah Gwynne

  • Richard Harrop

  • Robert Jones

  • Robert Hills

  • Awen Gallimore

  • Andrew Godkin

Medical Centers

  • Cardiff University School of Medicine, Cardiff, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • Oxford BioDynamics, Oxford, United Kingdom

  • South West Wales Cancer Institute, Swansea, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Carboxypeptidase M

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • MVA-5T4

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved